Teva launches generic blood pressure treatments

By GLOBES
April 2, 2012 11:43

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced Monday that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, its generic versions of Sanofi Aventis’s high blood pressure treatments, Avapro and Avalide Tablets.

Teva reports that the brand products had annual sales of approximately $464 million and $124 million, respectively in the US, according to IMS sales data.

As the first company to file Abbreviated New Drug Applications (ANDA) containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.

Related Content

Breaking news
August 15, 2018
Turkish court rejects U.S. pastor's appeal, upper court yet to rule, lawyer says

By REUTERS